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Abstract
Background Use of rate/rhythm control is essential to control symptoms in patients with atrial fibrillation (AF). Recently, 
the EAST-AFNET 4 trial described how early rhythm control strategy was associated with a lower risk of adverse clinical 
outcomes.
Objectives The aim was to evaluate the real-world applicability and impact of an early rhythm control strategy in patients 
with AF.
Methods Use of an early rhythm control strategy was assessed in a European cohort of AF patients derived from the EHRA-
ESC EORP-AF General Long-Term Registry. Early rhythm control was defined as use of antiarrhythmic drugs or cardiover-
sion/catheter ablation. The primary outcome included cardiovascular death, stroke, acute coronary syndrome, and worsening 
of heart failure. Quality of life and health-care resource usage were also assessed as outcomes.
Results Among the 10,707 patients evaluated for eligibility to EAST-AFNET 4, a total of 3774 (34.0%) were included. Early 
rhythm control was associated with better quality of life, but with greater use of health-care resources. During follow-up, 
the primary outcome occurred less often in early rhythm control patients than in those with no rhythm control (13.6% vs. 
18.5%, p < 0.001). In the multivariate adjusted Cox regression model, no significant difference was found between no rhythm 
control and early rhythm control, for the primary outcome. No difference in the primary outcome between early rhythm 
control and ‘no rhythm control patients’ adherent to Atrial fibrillation Better Care (ABC) pathway’ was evident (p = 0.753)
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Conclusions Use of an early rhythm control strategy was associated with a lower rate of major adverse events, but this dif-
ference was non-significant on multivariate analysis, being mediated by differences in baseline characteristics and clinical 
risk profile. Early rhythm control was associated with a higher use of health-care resources and risk of hospital admission, 
despite showing better quality of life.
Graphic abstract
Keywords Atrial fibrillation · Rhythm control · Rate control · Outcomes
Introduction
Patient-centred, symptom-directed decisions on rate or 
rhythm control are pivotal considerations for the clinical 
management of patients with atrial fibrillation (AF). This 
approach is recommended by the European Society of Car-
diology (ESC) 2020 Clinical Guidelines for AF management 
[1] and is part of the ‘B’ criterion of the Atrial fibrillation 
Better Care (ABC) pathway for the integrated care manage-
ment of patients with AF [2].
It has long been debated whether rate vs. rhythm control 
strategy could have differential impact on major clinical 
outcomes, especially the risk of all-cause death occurrence 
[3–5]. A more recent approach advocated is that a back-
ground rate control therapy is needed in all AF patients, with 
additional rhythm control strategies to mitigate symptom 
burden [1, 6].
The “Early Treatment of Atrial Fibrillation for Stroke Pre-
vention Trial” (EAST-AFNET 4) study [7] tested the hypoth-
esis that early initiation of rhythm control therapy conferred 
an advantage in terms of the risk of major adverse events. 
Over a median 5.1 years of follow-up, the trial reported a 
21% relative risk reduction (6–34% CI) for a composite pri-
mary outcome of cardiovascular (CV) death, stroke, acute 
coronary syndrome and hospitalization/worsening of heart 
failure [7]. Given that the intervention arm had structured 
follow-up and a ‘package of care’, the applicability of this 
trial to real world clinical practice requires further study.
In this ancillary analysis from the ESC-European 
Heart Rhythm Association (EHRA) EURObservational 
Research Programme (EORP) AF General Long-Term 
Registry, the aim of this study was to utilize a large 
real-world cohort of European AF patients: first, to 
determine how many patients would be able to fulfil the 
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EAST-AFNET 4 inclusion criteria; and second, to test the 
impact of an early rhythm control strategy on the use of 
health care resources, quality of life and major adverse 
events.
Methods
The ESC-EHRA EORP AF General Long-Term Registry 
is a multicentre observational registry held by the ESC 
and endorsed by the EHRA, with the General Long-Term 
Registry preceded by the EORP-AF General Pilot Regis-
try [8–11]. The EORP-AF General Long-Term Registry 
is a prospective, observational, multicentre registry estab-
lished by ESC in 27 participating countries. The study 
enrolled consecutive patients with AF presenting in 250 
cardiology practices, in both in- and outpatient settings. 
The detailed description of the study design, baseline 
characteristics and 1-year follow-up results have been 
provided previously [12, 13]. Briefly, all patients enrolled 
had AF documented within 12 months before enrolment 
on the basis of objective electrocardiographic evalua-
tion. All patients were aged ≥ 18 years and provided writ-
ten informed consent. Enrolment was undertaken from 
October 2013 to September 2016, with 1-year and 2-year 
follow-up. Institutional review board approved the study 
protocol for each country, and the study was performed 
according to the EU Note for Guidance on Good Clini-
cal Practice CPMP/ECH/135/95 and the Declaration of 
Helsinki.
Symptomatic status was defined according to EHRA 
score [1]. Thromboembolic risk was defined according 
to the  CHA2DS2-VASc score [14], with bleeding risk 
defined by the HAS-BLED score [15]. Multimorbidity 
was defined as the concomitant presence of at least two 
different long-term comorbidities. Frailty was defined on 
the basis of a 38-items frailty index of ≥ 0.25, accord-
ing to Rockwood and Mitnitski [16]. Polypharmacy was 
classified as the concomitant prescription of ≥ 5 drugs 
[17]. Adherence of clinical management to the ‘Atrial 
fibrillation Better Care’ (ABC) pathway was retrospec-
tively defined in this cohort, as previously reported [18]. 
Briefly, the ABC pathway has been proposed to stream-
line integrated care and holistic management in AF 
patients and is based on the following: (i) avoid stroke 
with anticoagulation; (ii) better symptom management 
with patient-centred symptom-directed decisions on rate 
or rhythm control; (iii) cardiovascular risk factor and 
comorbidities optimization including lifestyle changes 
[2]. Adherence to the ABC pathway has consistently been 
associated with reduction in risk for major clinical out-
comes associated with AF [19].
Evaluation of eligibility to EAST‑AFNET 4 trial 
criteria
To understand how many patients in the current cohort 
would have been eligible to be enrolled in the EAST-AFNET 
4, we applied the same inclusion criteria to our population 
[20]. All the patients included in the EORP-AF General 
Long-Term Registry were ≥ 18 years and diagnosed with AF 
within 12 months of enrolment. Hence, we included all the 
patients that were aged ≥ 75 years or had a clinical history 
positive for previous stroke or transient ischaemic attack. 
Additionally, we included all the patients that fulfilled at 
least two of the following criteria: (i) age ≥ 65 years; (ii) 
female sex; (iii) hypertension; (iv) diabetes mellitus; (v) 
previous myocardial infarction or any coronary revasculari-
zation procedure; (vi) stable heart failure (NYHA II or ejec-
tion fraction < 50%); (vii) left ventricular hypertrophy: (viii) 
chronic kidney disease (creatinine clearance 15–59 mL/
min); (ix) peripheral arterial disease.
Definition of early rhythm control
Early rhythm control was defined at the moment of enrol-
ment visit or discharge following hospital admission. All 
those patients who received a rhythm control intervention 
during the index episode, such as electrical cardioversion, 
pharmacological cardioversion, catheter ablation, or were 
prescribed an antiarrhythmic drug (Class Ia, Class Ic, Class 
III) at discharge, were included in the ‘early rhythm control’ 
group.
All the other patients prescribed beta blockers, digoxin, or 
non-dihydropyridine calcium-channel blockers, as rate con-
trol drugs, were included in the ‘no rhythm control’ group.
Evaluation of quality of life
Quality of life was evaluated at baseline and 1-year follow-
up using the EQ-5D-5L questionnaire, a generic, extensively 
validated, easy to use instrument that consists of two parts: 
the EQ-5D descriptive system and the EQ visual analogue 
scale (https:// euroq ol. org/ eq- 5d- instr uments/ eq- 5d- 5l- 
about/). The descriptive system consists of five dimen-
sions (mobility, self-care, usual activities, pain/discomfort 
and anxiety/depression) with five possible levels for each 
dimension (no problems, slight problems, moderate prob-
lems, severe problems and extreme problems), generating 
 55 = 3125 unique health states. According to a previous 
report, using the UK trade-off value set we translated each 
of the levels into a single numeric value, with the lowest val-
ues corresponding to better health [21]. Furthermore, com-
bining the single values, we translated the five-digit health 
state into a single index, the Health Utility Score (HUS) by 
subtracting each value from 1. The best possible health in 
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each dimension (= 11,111) corresponded to an HUS of 1.0 
(perfect health). An HUS of 0 is equivalent to death. The 
visual analogue scale was used for patients to self-rate their 
current health status, ranging from 0 (worst health imagina-
ble) to 100 (best health imaginable).
Evaluation of health‑care resources use
We examined the differential use of health-care resources 
according to the use of early rhythm control. In patients 
enrolled during hospitalization, we evaluated the overall 
length of stay. Further, we analysed the occurrence and num-
ber of cardiology and internal medicine/general practitioner 
visits, as well as the emergency room (ER) admissions dur-
ing the follow-up observation (at 1 and 2 years of follow-up).
Also, to account comprehensively for the use of health-
care resources, we evaluated the occurrence of hospital 
admission/readmission throughout follow-up observation, 
as follows: (i) any readmission; (ii) any CV readmission; 
(iii) any AF readmission; (iv) any CV non-AF readmission; 
and (v) any non-CV readmission.
Major adverse events
The primary main outcome of the study was equivalent to 
the original EAST-AFNET 4 trial primary outcome, being 
a composite of (i) CV death; (ii) any stroke; (iii) worsening 
heart failure; and (iv) acute coronary syndrome. The second-
ary clinical outcomes were: (i) major adverse cardiovascular 
events (MACEs): as the composite of any thromboembolic 
events, any acute coronary syndrome and CV death; and (ii) 
all-cause death.
Statistical analysis
Continuous variables were expressed as mean SD or 
median IQR and differences across the groups were evalu-
ated according to Student’s T test and Mann–Whitney U 
test, respectively. Categorical variables were expressed as 
counts and percentages and differences across groups were 
evaluated according to the Chi-square test. A univariate 
and multivariate logistic regression model was compiled to 
evaluate the clinical factors associated with the choice of 
early rhythm control.
To evaluate the relationship between the use of early 
rhythm control and length of hospital stay, in addition to 
the number of medical visits during the follow-up, we per-
formed a linear regression analysis adjusted for type of AF, 
 CHA2DS2-VASc score and EHRA score. To analyse the 
association between the use of early rhythm control and the 
occurrence of medical visits, a logistic regression model was 
used, adjusted for type of AF,  CHA2DS2-VASc score and 
EHRA score. We also performed a linear regression analysis 
adjusted for type of AF,  CHA2DS2-VASc score and EHRA 
score to evaluate the relationship between the use of early 
rhythm control and quality of life measures at baseline and 
throughout follow-up. The association between the use of 
early rhythm control and readmission outcomes was tested 
using a logistic regression model, adjusted for type of AF, 
 CHA2DS2-VASc score, EHRA score and use of OAC.
Differences in cumulative risk for the main study out-
come were evaluated using log-rank tests and Kaplan–Meier 
curves. To investigate the independent associations between 
the use of early rhythm control and the primary and main 
secondary clinical outcomes, a Cox regression analysis 
was performed. Two different models were constructed: (i) 
adjusted for type of AF,  CHA2DS2-VASc score and EHRA 
score and use of oral anticoagulant (OAC); (ii) adjusted for 
type of AF, EHRA score, age, sex, hypertension, diabetes 
mellitus, heart failure, severe coronary artery disease, val-
vular disease, left ventricular hypertrophy, peripheral artery 
disease, stroke/transient ischaemic attack, chronic kidney 
disease, chronic obstructive pulmonary disease, malignancy 
and use of OAC. Lastly, we performed a sensitivity analysis 
regarding the occurrence of study primary outcome, com-
paring the early rhythm control strategy to a ‘no rhythm 
control’ approach adherent to the ABC pathway.
All linear regression analyses were reported as Beta coef-
ficient and 95% CI. All logistic regression analyses results 
were reported as OR and 95% CI. All Cox regression analy-
ses results were reported as HR and 95% CI. A two-sided 
p < 0.05 was considered statistically significant. All analy-
ses were performed using SPSS statistical software version 
25.0.0.1 (IBM, NY, USA) for MacOS.
Results
From the original 11,096 patients enrolled in the EORP-
AF, 10,707 (96.5%) were evaluated for eligibility to EAST-
AFNET 4 inclusion criteria, due to missing data for the 
variables use to evaluate eligibility. Overall, 3774 (34.0%) 
patients fulfilled the study’s inclusion criteria and were 
selected for this analysis. Among those not selected, 2654 
(38.3%) did not fulfil the study main criteria; 3682 (53.1%) 
did not fulfil the study additional criteria; 4013 (57.9%) had 
long-standing persistent or permanent AF or did not report 
the type of AF.
Comparing EORP-AF patients included in this analy-
sis to those not included, included patients were older, 
with higher  CHA2DS2-VASc and HAS-BLED scores and 
with more comorbidities and prescribed medications (all 
p < 0.001). EORP-AF patients qualifying for inclusion had a 
higher proportion of those aged ≥ 75 years, were more likely 
to have persistent AF and had a higher symptom burden 
compared to those enrolled in the EAST-AFNET 4 study 
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(Table 1). Also, EAST-AFNET 4 patients reported higher 
proportions of hypertension and diabetes mellitus, while 
EORP-AF patients had more structural heart disease (heart 
failure, severe coronary artery disease, valvular disease, left 
ventricular hypertrophy) (Table 1).
Determinants of early rhythm control
Among EORP-AF patients, 2052 (54.4%) were treated 
according to an early rhythm control strategy and 1722 
(45.6%) with no rhythm control at baseline. Patients pre-
scribed early rhythm control were younger, more likely male, 
with persistent AF and a higher burden of AF symptoms. 
The early rhythm control group had more prevalent hyper-
tension, but less comorbidities, with lower thromboembolic 
and bleeding risk factors, and a greater proportion receiving 
OAC (Table 1). Mean (SD) time from AF diagnosis to enrol-
ment was not significantly different between patients treated 
with and without early rhythm control [48.6 (84.4) days vs. 
51.2 (88.6) days, respectively; p = 0.426], nor was the mean 
(SD) time from enrolment to discharge [0.4 (14.1) days vs. 
1.5 (16.7) days, respectively; p = 0.381].
At discharge, among patients not prescribed early rhythm 
control, a rate control strategy based on the use of beta 
blockers was most commonly used (63.3%), while 29.0% 
were managed with a combination of rate control drugs 
and only a minority were treated with digoxin only (2.1%) 
and non-dihydropyridine calcium-channel blockers (5.5%). 
(Fig. 1). In the early rhythm control group, use of a combi-
nation antiarrhythmic strategy (antiarrhythmic drugs + car-
dioversion/ablation) was most common (36.1%), with sole 
use of antiarrhythmic drugs only in 28.2% (Fig. 1). Electric 
cardioversion only was used in 22.5% of patients, pharma-
cological cardioversion only in 9.9% and catheter ablation 
only in 3.3% (Fig. 1).
Based on the differences in baseline characteristics, uni-
variate logistic regression analysis for the clinical factors 
associated with the use of an early rhythm control strategy, 
followed by a multivariate model (Table S1), showed that 
paroxysmal and persistent AF, progressively increasing 
symptom burden and presence of hypertension were sig-
nificantly associated with the use of an early rhythm control 
strategy. Increasing age, higher NYHA class and concomi-
tant diabetes mellitus, stroke/transient ischaemic attack and 
chronic obstructive pulmonary disease were all inversely 
associated with early rhythm control (Table S1).
Evaluation of quality of life
At baseline, evaluation of quality of life showed that 
patients managed with early rhythm control were more 
able to attend to their self-care (p = 0.001) and their usual 
activities (p < 0.001), but were more likely anxious, even 
after adjustment for  CHA2DS2-VASc score, type of AF and 
EHRA score (Table 2). In the multivariate analysis, at 1-year 
follow-up, those patients with early rhythm control had bet-
ter levels of mobility (p < 0.001), self-care (p = 0.009) and 
participation in their usual activities (p = 0.005), with an 
overall better health state according to the HUS (p = 0.002), 
compared to those not prescribed with an early rhythm con-
trol. At 2 years follow-up, patients prescribed early rhythm 
control reported less impairment in all five dimensions of 
the EQ-5D-5L questionnaire and a better overall health state 
according to both HUS (p < 0.001) and VAS (p = 0.053), 
after adjustment for  CHA2DS2-VASc score, type of AF and 
EHRA score (Table 2).
Evaluation of health‑care resources use
Use of health-care resources is reported in Table 3. Patients 
managed with early rhythm control attended more cardiol-
ogy and internal medicine/general practitioner appointments 
at both follow-up time points (all p < 0.001) (Table 3, upper 
panel).
Among hospitalized patients, those prescribed early 
rhythm control had a shorter mean hospital stay, even after 
adjustment (p = 0.001) (Table 3, lower panel). Among those 
who attended cardiology visits, those with early rhythm 
control reported a higher number of visits both at 1 year 
(p < 0.001) and 2 years (p = 0.023) of follow-up. Among 
patients attending internal medicine/general practitioner 
visits, those with early rhythm control attended more often 
within the first year of follow-up than those with ‘no rhythm 
control’ (p = 0.015).
Patients treated with an early rhythm control strategy had 
a higher rate of any readmission, and admissions related to 
CV reasons or AF (all p < 0.001) (Table 3). Logistic regres-
sion, adjusted for type of AF, EHRA score,  CHA2DS2-VASc 
score and use of OAC, found that an early rhythm control 
strategy was associated with higher odds of any hospital 
readmission, any CV readmission and any AF readmission 
(Table 3).
Major adverse events
Follow-up data were available for 3354 (88.9%) of the 
patients. Over a mean (SD) follow-up of 675.4 (181.3) 
days, a total of 532 (14.1%) EAST-AFNET 4 defined pri-
mary outcome events were reported with an overall inci-
dence of 8.9 per 100 patient-years. Death occurred in 321 
(8.5%) and 380 (10.1%) experienced MACEs. Compared 
to those treated with an early rhythm control approach, 
the no rhythm control group had a higher proportion of 
patients with the EAST-AFNET 4 defined primary out-
come, MACEs and all-cause death events (Table 4). The 
incidence of EAST-AFNET 4 defined primary outcome 
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Table 1  Baseline characteristics in EAST-AFNET 4 and EORP-AF and according to early rhythm control prescription
Variables EAST-AFNET 4 (N = 2789) EORP-AF (N = 3774) No rhythm control 
(N = 1722)
Early rhythm con-
trol (N = 2052)
p*
Age, years mean (SD) 70.3 (8.3) 69.8 (10.4) 71.9 (10.3) 68.0 (10.2) < 0.001
Age, years median [IQR] 71 [66–76] 71 [63–78] 74 [66–79] 69 [62–76] < 0.001
Age ≥ 75 years, n (%) 812 (29.1) 1483 (39.3) 855 (49.7) 628 (30.6) < 0.001
Male sex, n (%) 1496 (53.6) 2026 (53.7) 878 (51.0) 1148 (55.9) 0.002
BMI, kg/m2 median [IQR] 28.6 [25.5–32.1] 27.8 [24.8–31.2] 27.5 [24.6–31.2] 27.9 [25.0–31.3] 0.024
Type of AF, n (%) < 0.001
 First detected 1048 (37.6) 1031 (27.3) 564 (32.8) 467 (22.8)
 Paroxysmal 994 (35.7) 1538 (40.8) 742 (43.1) 796 (38.8)
 Persistent 743 (26.7) 1205 (31.9) 416 (24.2) 789 (38.5)
EHRA score, n (%) < 0.001
 EHRA I 801 (30.4) 1390 (36.8) 784 (45.5) 606 (29.5)
 EHRA II 1358 (51.6) 1465 (38.8) 581 (33.7) 884 (43.1)
 EHRA III 447 (17.0) 808 (21.4) 310 (18.0) 498 (24.3)
 EHRA IV 27 (1.0) 110 (2.9) 47 (2.7) 63 (3.1)
Hypertension, n (%) 2450 (87.8) 2559 (68.0) 1122 (65.4) 1437 (70.1) 0.002
Diabetes mellitus, n (%) 694 (24.9) 860 (22.8) 440 (25.6) 420 (20.5) < 0.001
NYHA class, n (%) < 0.001
 No HF 1819 (65.3) 2360 (62.5) 1019 (59.2) 1341 (65.4)
 I 331 (11.9) 239 (6.3) 125 (7.3) 114 (5.6)
 II 514 (18.5) 712 (18.9) 325 (18.9) 387 (18.9)
 III 120 (4.3) 396 (10.5) 214 (12.4) 182 (8.9)
 IV – 67 (1.8) 39 (2.3) 28 (1.4)
Prior stroke/TIA, n (%) 328 (11.8) 379 (10.1) 191 (11.2) 188 (9.2) 0.049
Severe CAD, n (%) 479 (17.2) 827 (21.9) 392 (22.8) 435 (21.2) 0.247
Valvular disease, n (%) 1251 (45.0) 1807 (48.6) 847 (50.3) 960 (47.2) 0.064
LVH, n (%) 132 (4.7) 988 (28.5) 463 (30.1) 525 (27.3) 0.070
PAD, n (%) 122 (4.4) 303 (8.1) 142 (8.4) 161 (7.9) 0.608
CKD, n (%) 351 (12.6) 454 (12.0) 234 (13.6) 220 (10.7) 0.006
COPD, n (%) 209 (7.5) 279 (7.4) 168 (9.8) 111 (5.4) < 0.001
Malignancy, n (%) 0.003
 No malignancy 2563 (92.2) 3467 (91.9) 1560 (90.6) 1907 (92.9)
 Active malignancy 19 (0.7) 79 (2.1) 52 (3.0) 27 (1.3)
 Prior malignancy 197 (7.1) 216 (5.7) 104 (6.0) 112 (5.5)
CHA2DS2-VASc, mean (SD) 3.3 (1.3) 3.3 (1.6) 3.6 (1.6) 3.1 (1.5) < 0.001
CHA2DS2-VASc, median [IQR] 3 [2–4] 3 [2–4] 4 [2–5] 3 [2–4] < 0.001
HAS-BLED, mean (SD) – 1.6 (1.0) 1.7 (1.1) 1.5 (1.0) < 0.001
HAS-BLED, median [IQR] – 2 [1, 2] 2 [1, 2] 1 [1, 2] < 0.001
Multimorbidity, n (%) – 2681 (83.3) 1218 (84.3) 1463 (82.4) 0.158
Frailty, n (%) – 555 (21.7) 236 (20.6) 319 (22.5) 0.246
Polypharmacy, n (%) – 2375 (63.3) 999 (58.3) 1376 (67.5) < 0.001
ABC pathway adherence, n (%) – 758 (29.9) 344 (29.3) 414 (30.5) 0.483
ABC pathway criteria, n (%) – 0.335
 0 59 (2.3) 33 (2.8) 26 (1.9)
 1 494 (19.5) 239 (20.3) 255 (18.8)
 2 1221 (48.2) 560 (47.6) 661 (48.7)
 3 758 (29.9) 344 (29.3) 414 (30.5)
Pharmacological treatments
 Any antiplatelet, n (%) 455 (16.4) 921 (24.4) 441 (25.6) 480 (23.4) 0.111
 Any OAC, n (%) 2517 (90.5) 3255 (86.3) 1426 (82.8) 1829 (89.2) < 0.001
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ABC atrial fibrillation better care, AF atrial fibrillation, BMI body mass index, CAD coronary artery disease, CKD chronic kidney disease, 
COPD chronic obstructive pulmonary disease, EHRA European Heart Rhythm Association, HF heart failure, IQR interquartile range, LVH left 
ventricular hypertrophy, NYHA New York Heart Association, PAD peripheral artery disease, SD standard deviation, TIA transient ischaemic 
attack
*p value is referred to the comparison between no rhythm control and early rhythm control
Table 1  (continued)
Variables EAST-AFNET 4 (N = 2789) EORP-AF (N = 3774) No rhythm control 
(N = 1722)
Early rhythm con-
trol (N = 2052)
p*
 Any VKA, n (%) – 1644 (43.6) 687 (39.9) 957 (46.7) < 0.001
 Any NOAC, n (%) – 1613 (42.8) 740 (43.0) 873 (42.6) 0.777
 ACEi/ARBs, n (%) 1932 (69.4) 2541 (67.4) 1156 (67.3) 1385 (67.5) 0.875
 Diuretics, n (%) 1120 (40.3) 1900 (50.4) 902 (52.5) 998 (48.7) 0.020
 MRAs, n (%) 182 (6.5) 577 (15.3) 276 (16.1) 301 (14.7) 0.240
 Statins, n (%) 1196 (43.0) 1832 (48.6) 843 (49.0) 989 (48.3) 0.636
 Oral antidiabetics, n (%) 459 (16.5) 599 (15.9) 314 (18.3) 285 (13.9) < 0.001
 Insulin, n (%) 121 (4.3) 205 (5.4) 102 (5.9) 103 (5.0) 0.220
Fig. 1  Distribution of rate/rhythm control treatments according to groups at baseline. BBs beta blockers, CA catheter ablation, CCBs calcium-
channel blockers, ECV electric cardioversion, PCV pharmacological cardioversion
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was 10.8 per 100 patient-years in patients with no rhythm 
control and 7.4 per 100 patient-years in patients with 
early rhythm control. Kaplan–Meier curves for the EAST-
AFNET 4 trial defined primary outcome showed that an 
early rhythm control strategy was associated with a pro-
gressively lower cumulative risk (p < 0.001) (Fig. 2).
Finally, a Cox regression analysis was performed to 
establish the association between use of an early rhythm 
control strategy and the risks of primary and secondary 
outcomes (Table 5). While the univariate analysis showed 
that prescription of an early rhythm control strategy was 
associated with a lower risk for all primary and secondary 
outcomes, the progressive adjustment process (Model 1 
adjusted for type of AF, EHRA score,  CHA2DS2-VASc 
score and use of OAC; Model 2 adjusted for type of AF 
EHRA score, all comorbidities evaluated at baseline and 
use of OAC) showed a gradual and subsequent loss in 
association, with the fully adjusted Model 2 showing no 
significant differences between patients treated with and 
without an early rhythm control strategy (HR 0.84, 95% CI 
0.66–1.19 for EAST-AFNET 4 defined primary outcome; 
HR 0.95, 95% CI 0.73–1.12 for MACEs; HR 0.96, 95% CI 
0.75–1.24 for all-cause death).
In the final multivariable model for the EAST-AFNET 4 
defined primary outcome, heart failure was associated with 
a nonsignificant trend for increased risk (HR: 1.21, 95% CI 
0.98–1.50, p = 0.075). For the occurrence of MACEs, par-
oxysmal AF was associated with an increased risk of events 
compared to persistent AF (HR: 1.42, 95% CI 1.02–1.98, 
p = 0.040).
Sensitivity analysis
We conducted a sensitivity analysis comparing the occur-
rence of the primary outcome in patients managed with early 
rhythm control and those with no rhythm control approach 
but adherent to the ABC pathway management. We selected 
all patients with data on ABC pathway adherence (2532, 
67.1%) and compared those managed with early rhythm con-
trol (1356, 53.6%), to those not treated with rhythm control 
Table 2  Quality of life indicators according to early rhythm control
Bold values depict significant association
CI confidence interval; for other acronyms please see previous tables’ legends
*Adjusted for  CHA2DS2-VASc score, type of AF, EHRA score
No rhythm control Early rhythm control p Early rhythm control p
Beta (95% CI)*
Baseline
 EQ-5D-5L mobility 0.049 (0.063) 0.043 (0.061) 0.019 − 0.003 (− 0.007/0.001) 0.156
 EQ-5D-5L self-care 0.020 (0.039) 0.014 (0.035) < 0.001 − 0.005 (0.007/ − 0.002) 0.001
 EQ-5D-5L usual activities 0.037 (0.047) 0.031 (0.044) < 0.001 − 0.006 (− 0.009/ − 0.003) < 0.001
 EQ-5D-5L pain/discomfort 0.049 (0.068) 0.044 (0.063) 0.024 − 0.004 (− 0.009/0.000) 0.062
 EQ-5D-5L anxiety 0.046 (0.066) 0.054 (0.072) 0.001 0.007 (0.002/0.012) 0.004
 Health utility score 0.80 (0.21) 0.81 (0.19) 0.068 0.010 (− 0.004/0.025) 0.142
 Visual analogue scale 68.3 (20.6) 68.3 (20.8) 0.992 0.093 (− 1.486/1.673) 0.908
1-year follow-up
 EQ-5D-5L mobility 0.046 (0.059) 0.036 (0.056) < 0.001 − 0.009 (− 0.014/ − 0.004) < 0.001
 EQ-5D-5L self-care 0.018 (0.035) 0.013 (0.033) 0.002 − 0.004 (− 0.007/ − 0.001) 0.009
 EQ-5D-5L usual activities 0.033 (0.042) 0.027 (0.041) 0.001 − 0.005 (− 0.009/ − 0.002) 0.005
 EQ-5D-5L pain/discomfort 0.044 (0.067) 0.039 (0.062) 0.056 − 0.005 (− 0.010/0.001) 0.118
 EQ-5D-5L anxiety 0.042 (0.066) 0.040 (0.057) 0.536 − 0.004 (− 0.009/0.002) 0.197
 Health utility score 0.817 (0.203) 0.844 (0.185) 0.001 0.026 (0.009/0.043) 0.002
 Visual analog scale 69.7 (19.8) 70.9 (19.8) 0.169 1.283 (− 0.505/3.071) 0.159
2 years follow-up
 EQ-5D-5L mobility 0.051 (0.062) 0.040 (0.056) < 0.001 − 0.009 (− 0.015/ − 0.004) 0.001
 EQ-5D-5L self-care 0.021 (0.040) 0.012 (0.027) < 0.001 − 0.009 (− 0.012/ − 0.005) < 0.001
 EQ-5D-5L usual activities 0.038 (0.045) 0.028 (0.041) < 0.001 − 0.008 (− 0.012/ − 0.004) < 0.001
 EQ-5D-5L pain/discomfort 0.048 (0.068) 0.039 (0.062) 0.004 − 0.008 (− 0.014/ − 0.001) 0.016
 EQ-5D-5L anxiety 0.043 (0.065) 0.037 (0.058) 0.052 − 0.007 (− 0.013/ − 0.001) 0.020
 Health utility score 0.80 (0.21) 0.84 (0.18) < 0.001 0.042 (0.023/0.060) < 0.001
 Visual analogue scale 69.8 (19.4) 72.1 (19.8) 0.016 1.943 (− 0.026/3.911) 0.053
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but managed with a clinical management adherent to the 
ABC pathway (344, 13.6%).
During follow-up, no difference in the cumulative risk 
of primary outcome between early rhythm control and no 
rhythm control adherent to ABC pathway was evident (log-
rank: 0.099, p = 0.753) (Fig. S1). Cox regression analysis 
confirmed no association between early rhythm control strat-
egy vs. no rhythm control ABC adherent management in 
univariate (HR: 1.03, 95% CI 0.71–1.49) or multivariable 
(HR: 0.99, 95% CI 0.65–1.52) analyses.
Discussion
In this secondary analysis from the ESC-EHRA EORP-
AF General Long-Term Registry, only about one-third of 
European AF patients would be eligible for the original 
EAST-AFNET 4 study. Second, patients treated with early 
rhythm control were more likely to be younger, with less 
comorbidities, were more symptomatic and had a more 
established form of AF. Third, early rhythm control was 
associated with better quality of life during follow-up, but 
with an increased use of health-care resources, as well as a 
higher risk of hospital readmissions. Fourth, early rhythm 
control was associated with a lower rate of the composite 
Table 3  Use of health-care resources according to early rhythm control use
Bold values depict significant association
1Y 1-year follow-up, 2YR 2 years follow-up, ER emergency room, GP general practitioner, IM internal medicine, OR odds ratio; for other acro-
nyms please see previous tables’ legends.
*Adjusted for  CHA2DS2-VASc score, type of AF, EHRA score
† Adjusted for  CHA2DS2-VASc score, type of AF, EHRA score, use of OAC
No rhythm control Early rhythm control p Early rhythm control p
OR (95% CI)*
Cardiology visits 1Y, n (%) 940 (68.3) 1386 (83.0) < 0.001 2.07 (1.73–2.47) < 0.001
IM/GP visits 1Y, n (%) 481 (43.9) 822 (58.9) < 0.001 1.87 (1.58–2.21) < 0.001
ER admissions 1Y, n (%) 290 (21.6) 371 (22.4) 0.577 1.08 (0.90–1.29) 0.422
Cardiology visits 2Y, n (%) 738 (61.6) 1130 (76.2) < 0.001 1.88 (1.58–2.23) < 0.001
IM/GP visits 2Y, n (%) 430 (42.1) 760 (58.9) < 0.001 2.02 (1.70–2.40) < 0.001
ER admissions 2Y, n (%) 181 (15.8) 242 (16.8) 0.497 1.08 (0.87–1.35) 0.482
No rhythm control Early rhythm control p Early rhythm control p
Beta (95% CI)*
Length of stay, days mean (SD) 7.6 (7.1) 5.9 (6.7) < 0.001 − 0.992 (− 1.572/ − 0.412) 0.001
Cardiology visits 1Y, N mean (SD) 2.4 (1.9) 2.7 (2.2) < 0.001 0.349 (0.168/0.530) < 0.001
IM/GP visits 1Y, N mean (SD) 3.9 (3.4) 4.6 (3.9) 0.004 0.589 (0.115/1.062) 0.015
ER admissions 1Y, N mean (SD) 1.7 (1.3) 1.7 (1.4) 0.704 0.005 (− 0.209/0.219) 0.963
Cardiology visits 2Y, N mean (SD) 2.0 (1.4) 2.2 (1.8) 0.004 0.184 (0.025/0.342) 0.023
IM/GP visits 2Y, N mean (SD) 3.5 (3.4) 3.7 (3.3) 0.505 0.094 (− 0.348/0.536) 0.676
ER admissions 2Y, N mean (SD) 1.6 (1.2) 1.6 (1.3) 0.610 0.061 (− 0.193/0.315) 0.637
No rhythm control Early rhythm control p Early rhythm control p
OR (95% CI)†
Any readmission, n (%) 624 (38.6) 857 (46.2) < 0.001 1.34 (1.16–1.54) < 0.001
Any CV readmission, n (%) 415 (25.7) 607 (32.7) < 0.001 1.40 (1.20–1.63) < 0.001
Any AF readmission, n (%) 205 (12.7) 408 (22.0) < 0.001 1.76 (1.45–2.12) < 0.001
Any CV non-AF readmission, n (%) 303 (18.8) 317 (17.1) 0.203 0.95 (0.79–1.14) 0.540
Any non-CV readmission, n (%) 207 (12.8) 213 (11.5) 0.232 0.91 (0.74–1.13) 0.369
Table 4  Major clinical outcomes comparing early rhythm control ver-
sus no rhythm control in the EORP-AF registry patients eligible for 
EAST-AFNET 4
AF atrial fibrillation, CV cardiovascular, MACEs major adverse car-
diovascular events




287 (18.5) 245 (13.6) < 0.001
MACEs 204 (12.5) 176 (9.4) 0.003
All-cause death 191 (11.9) 130 (6.7) < 0.001
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primary outcome (CV death, any stroke, acute coronary 
syndrome or worsening heart failure). In the fully adjusted 
analyses, there were no statistical differences for the pri-
mary outcome, MACEs, and all-cause death for patients 
treated with early rhythm control (Graphical Abstract).
The debate comparing rate vs. rhythm control has been 
running for the last 20 years. In the ‘Atrial Fibrillation 
Follow-Up Investigation of Rhythm Management’ study, 
4060 AF patients were randomized to rate vs. rhythm con-
trol strategies to establish if there were any differences in 
all-cause death. After 6 years of follow-up, this large trial 
did not find any differences in mortality between the two 
groups [22]. In the subsequent years, several other stud-
ies have shown a significant reduction of stroke risk and 
cardiovascular events, in patients managed with rhythm 
control strategies [23]. Conversely, other studies derived 
from observational registries report differences in event 
rates between patients treated with rate or rhythm control 
strategies, but these differences were no longer significant 
after adjustment for baseline characteristics [5, 24]. Sev-
eral large meta-analyses have failed to show any significant 
Fig. 2  Kaplan–Meier curves for EAST-AFNET 4 primary outcome. Black solid line = early rhythm control; black dotted line = no early rhythm 
control
Table 5  Cox regression analysis for main adverse events for those 
receiving early rhythm control versus no rhythm control
HR hazard ratio, MACEs major adverse cardiovascular events; for 
other acronyms please see previous tables’ legends
*Adjusted for type of AF, EHRA score,  CHA2DS2-VASc score, use 
of OAC
† Adjusted for type of AF, EHRA score, age, sex, hypertension, dia-
betes mellitus, heart failure, severe coronary artery disease, valvular 
disease, left ventricular hypertrophy, peripheral artery disease, stroke/
transient ischaemic attack, chronic kidney disease, chronic obstruc-
tive pulmonary disease, malignancy, use of OAC
Univariate Model 1* Model  2†




0.69 [0.57–0.83] 0.83 [0.68–1.01] 0.84 [0.66–1.19]
MACEs 0.70 [0.55–0.89] 0.88 [0.69–1.13] 0.95 [0.73–1.24]
All-cause death 0.56 [0.45–0.70] 0.73 [0.58–0.93] 0.96 [0.75–1.24]
Clinical Research in Cardiology 
1 3
differences in clinical outcomes between rate and rhythm 
control strategies [3, 4].
Other data from the ‘Outcomes Registry for Better 
Informed Treatment of Atrial Fibrillation’ and EORP-AF 
General Pilot registries report how in real-world clinical 
practice, rhythm control strategies are more commonly 
prescribed to younger and generally healthier patients, per-
haps directly influencing the lower rate of events in multi-
variate analysis [5, 24]. Nonetheless, the older trials were 
conducted > 2 decades ago and, since then, there has been 
greater recognition and understanding of electromechani-
cal substrate (and the possibility of early interventions to 
mitigate the so-called ‘atrial cardiomyopathy’ [25]) as well 
as the availability of improved (safer) drug therapies and 
catheter ablation approaches. Indeed, trial data regarding the 
use of catheter ablation in selected AF patients with heart 
failure show that using a rhythm control strategy may be 
associated with a lower rate of major adverse events [26, 27].
On this basis, the EAST-AFNET 4 trial investigators 
postulated that an early rhythm control could minimize AF-
induced atrial damage, hence reducing the occurrence of 
clinical adverse events [20]. In this trial involving 135 cen-
tres, a total of 2789 patients were enrolled and randomized 
to receive early rhythm control or usual care and followed 
up for a median of 5.1 years. The early rhythm control arm 
was associated with a significant reduction in the compos-
ite primary outcome of CV death/stroke/hospitalization for 
heart failure or acute coronary syndrome (HR 0.79, 95% CI 
0.66–0.94), particularly driven by reduction in CV death 
and stroke [7].
In the current analysis of the EORP-AF registry, a large 
cohort of European AF patients, only one-third of patients 
could be considered for management with early rhythm con-
trol based on the EAST-AFNET 4 criteria. Among those 
patients qualifying for early rhythm control, such patients 
were younger and with less comorbidities, consistent with an 
early rhythm control intervention recommended to younger 
and healthier patients. While a difference in risk of major 
adverse outcomes exists when comparing early rhythm 
control to no rhythm control, this difference may be partly 
due to the differences in baseline characteristics, as shown 
in the fully adjusted model. Our analysis also shows that 
patients managed with early rhythm control are more com-
monly monitored and undergo further medical treatments, 
as underlined by the increased use of health-care resources 
and the higher risk for hospital readmission. Conversely, an 
early rhythm control strategy was associated with an overall 
better quality of life, consistent with previous data [3]. Data 
from the ‘EdoxabaN vs. warfarin in subjectS UndeRgoing 
cardiovErsion of atrial fibrillation’ trial show how receiving 
a cardioversion procedure was significantly associated with 
an improved patients’ quality of life [28].
Indeed, early rhythm control as part of a structured 
follow-up regimen could partly explain the differences in 
clinical outcomes seen in the EAST-AFNET 4 trial, where 
the lower risk for the primary outcome could have been 
mediated by a better control and treatment of concomitant 
conditions [29–31]. Indeed, when directly comparing the 
early rhythm control group with the ABC pathway adherent 
patients, the absence of any difference in terms of primary 
outcome occurrence suggests that the beneficial effect of the 
early rhythm control could be attributed to a more compre-
hensive strategy of holistic care/management. Furthermore, 
the open label design in the EAST-AFNET-4 trial could have 
influenced recurring (and more common) medical checks.
Moreover, the higher incidence rates of the primary 
outcome both in patients with no rhythm control and early 
rhythm control, compared to the original study cohort’s 
event rates, underlines how our real-life cohort is signifi-
cantly at higher risk for outcomes compared to that seen 
in the selected population included within a randomized 
clinical trial. While this poses some limitations to the gen-
eralizability of EAST-AFNET 4 trial in real-life patients, 
it underlines that general AF patients have strong burden 
of risk related to the complexity of their overall clinical 
features, questioning whether the ‘one intervention fits all’ 
application of an early rhythm control approach irrespective 
of the clinical presentation is appropriate. Also, this given 
greater justification for integrated or holistic management of 
AF patients, consistent with the ESC AF guideline-recom-
mended ABC pathway [1].
Indeed, the use of a rhythm control intervention could 
be prioritized for those patients with a significant burden 
of symptoms, as part of a comprehensive management of 
AF patients. The use of rate and rhythm control to reduce 
the burden of symptoms is one of the pillars of the ABC 
pathway [1]. Such a structured approach to holistic AF care, 
including proactive risk evaluation and management, has 
been shown to be associated with improved clinical out-
comes, especially with a reduction in hospitalizations and 
clinical events [19, 32–34].
Limitations
This analysis has some limitations. Being a secondary analy-
sis of an observational registry, the original study design was 
not powered to examine differences in specific subgroups 
and for specific rhythm strategies. Since a higher burden of 
symptoms was associated with use of early rhythm control, 
we could hypothesize that this could represent a bias influ-
encing the use of health-care resources. The inclusion of 
EHRA score as covariate in the regression analyses regard-
ing the use of health-care resources would minimize such 
bias.
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Despite the use of adjusted analyses, differences in base-
line characteristics could have significantly influenced our 
results, especially with progressive ageing and incident 
comorbidities [35–38]. Finally, the non-randomized treat-
ment allocation of patients to the groups examined clearly 
limits the generalizability of our conclusions, raising the 
need of interpreting our data with caution. Furthermore, 
while we fully recognize that observational data are no sub-
stitute for clinical trials, we analysed a real-world European 
cohort that is nearly twofold in size compared to the original 
EAST-AFNET 4 trial, reflecting the generalizability of our 
results rather than the selective inclusion/exclusion criteria 
of trial cohorts.
Conclusions
In this secondary analysis of a large contemporary cohort 
of AF patients, only one-third of patients would have been 
eligible for inclusion into the EAST-AFNET 4 trial. Use 
of an early rhythm control strategy was associated with a 
lower rate of major adverse events, but this difference was 
non-significant on multivariate analysis, being mediated by 
differences in baseline characteristics and clinical risk pro-
file. Early rhythm control was associated with a higher use of 
health-care resources and risk of hospital admission, despite 
showing better quality of life.
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